Le Lézard
Classified in: Health
Subject: FDA

CrossRoads® Extremity Systems Announces Launch of the Active Stabilizationtm MPJ Implant System


MEMPHIS, Tenn., May 22, 2018 /PRNewswire/ -- CrossRoads® Extremity Systems, the Global Leader in Active Stabilizationtm, offering innovative foot & ankle fixation implant systems and services, announced that the Company has received FDA clearance for the DynaFORCE® Active Stabilizationtm MPJ Implant System. CrossRoads® Extremity Systems has the only MPJ Implant system on the market that combines stability of an anatomic plate with active compression of a nitinol clip, delivered to the operating room completely sterile packed.

MPJ Active Stabilization Implant System - *Patents Pending Worldwide

Scott Shawen, MD, from Charlotte, NC, one of the first users of the MPJ Active Stabilizationtm system states, "CrossRoads provides a comprehensive Active Stabilizationtm system that is easy to use. After more than 30 cases, I have found that the instrumentation is the most ergonomic on the market, making drilling and deployment of the compression clip and plate quick and simple." He continued to say, "Anecdotally, my midfoot fusion times have been cut in half. Additionally, my patients have earlier initiation of weight bearing. I look forward to using DynaFORCE® Active Stabilizationtm constructs on additional applications in the future."

About CrossRoads® Extremity Systems

CrossRoads was founded in 2014 and is headquartered in Memphis, TN. CrossRoads has experienced rapid growth through creative product development and a strong distributorship network. CrossRoads' goal is to provide a steady rhythm of novel and clinically relevant new products that distinguish it from other companies.

In addition to providing novel products, CrossRoads strives to find ways to help hospitals save money and improve efficiency. CrossRoads believes that as customers experience the EcoSMART® model of using high quality, surgical grade instruments in sterile kits, EcoSMART® Service will become the preferred model of surgeons, O.R. staff, and materials management.

For more information, please visit www.crextremity.com or www.activestabilization.com

©2018 CrossRoads Extremity Systems, LLC.  All Rights Reserved

Vernon Hartdegen
President & CEO of CrossRoads Extremity Systems, LLC
[email protected]

SOURCE CrossRoads Extremity Systems


These press releases may also interest you

at 12:24
West Physics Announces Acquisition of Tricord, Inc.
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:08
Roivios Secures FDA Breakthrough Device Designation for JuxtaFlow® RAD, Showcases Pioneering Data at Society of Cardiovascular Anesthesiologists Annual Meeting
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...

at 12:06
Burrell College of Osteopathic Medicine Achieves Highest Accreditation Status from AOA Commission on Osteopathic College Accreditation
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...

at 12:05
Radiance Biopharma to Present at LSX World Congress 2024
Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that...

at 12:01
Report from Orexo AB's annual general meeting, 26 April 2024
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be five with no deputy board...

More news about Health...


News published on and distributed by: